EthamsylateEthamsylate
MedChemExpress (MCE)
HY-B1074
2624-44-4
Etamsylate
99.49%
4°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light, stored under nitrogen)
Room temperature in continental US
may vary elsewhere.
Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis..
Ethamsylate (480 μM, 30 mim) prolongs lifetime of neutrophils[1]. Ethamsylate (0-100 μM, 3-8 h) inhibits migration and tubulogenesis on matrigel in endothelial cells[3]. Ethamsylate (0-100 μM, 48 h), inhibits the signaling of FGF/FGFR, decreases phosphorylation Levels of AKT and Erk1/2[3].
Ethamsylate (100 mg/kg, p.o., twice a day, three days) attenuates mutilated secondary pathogenesis and exhibits a neuroprotective role in mice of spinal cord injury[4].
| | | |
| | | | | |
[1]. Zawrotniak M, et al. Selected mucolytic, anti-inflammatory and cardiovascular drugs change the ability of neutrophils to form extracellular traps (NETs). Acta Biochim Pol. 2015
62(3):465-73. [Content Brief]
[2]. Kovács L, et al. Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro. Experientia. 1981 Nov 15
37(11):1182-3. [Content Brief]
[3]. Albiñana V, et al. Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition). TH Open. 2019 Jul 26
3(3):e230-e243. [Content Brief]
[4]. Dolma S, et al. Ethamsylate Attenuates Mutilated Secondary Pathogenesis and Exhibits a Neuroprotective Role in Experimental Model of Spinal Cord Injury. Neuroscience. 2022 Feb 21
484:26-37. [Content Brief]